Trial reportEuropean heart journal2022
Bone marrow activation in response to metabolic syndrome and early atherosclerosis.
Trial report in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410318 (Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors
Who cites it
44 citing papers in PubMed, 63 citations in OpenAlex.
- Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.Nature medicine · 2026Trial
- Roles of inflammation and metabolic dysfunction in cardiovascular diseases: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2026Review
- Spatially Distinct Bone Marrow Sites Are Asymmetrically Impacted by Inflammatory Cardiovascular Disease.JACC. Basic to translational science · 2026Article
- Review
- [EJNMMI research · 2026Article
- Telomere length dynamics do not predict subclinical atherosclerosis progression over a six-year period.GeroScience · 2026Article
- Article
- Hepatic steatosis associates with leukopoietic activity and atherosclerotic inflammation: mechanistic insights into cardiovascular risk.Metabolism: clinical and experimental · 2026Article
- The neuroimmune axis in cardiovascular disease: from immune activation to inflammatory resolution.Frontiers in immunology · 2026Review
- Association between chronic stress-related amygdala metabolic activity and distant metastasis in colorectal cancer.Frontiers in endocrinology · 2026Article
- Can Nuclear Imaging Detect Trained Immunity in Cardiovascular Disease?Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Age modulates the link between stress-related neural activity and mortality.Nature communications · 2025Article
- Developmental low-dose bisphenol A exposure leads to extensive transcriptome female masculinization and male feminization later in life.Communications medicine · 2025Article
- Neutrophil-to-Lymphocyte Ratio, Bone Marrow, and Visceral Fat Metabolism as Predictors of Future Cardiovascular Disease in an Asymptomatic Healthy Population.Journal of clinical medicine · 2025Article
- Article
- Relationship between CXCR4 and GNG4 in the Brain and Chronic Stress-Induced Atherosclerosis.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Anti-Inflammatory Therapy to Treat Atherothrombosis.Maedica · 2025Article
- Functional diversity of cardiac macrophages in health and disease.Nature reviews. Cardiology · 2025Review
- Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.Circulation research · 2025Review
- Role of Trained Immunity in Heath and Disease.Current cardiology reports · 2025Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsExperimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND
resultsWhole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden).
conclusionIn apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.